Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Retail LLMs promise raw computing power in edge settings. But what are the considerations that face decision-makers in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results